Cargando…
T53. USING ARTIFICIAL INTELLIGENCE PLATFORMS TO ENHANCE STUDY DESIGN IN SCHIZOPHRENIA TRIALS
BACKGROUND: Remote patient monitoring is critical in ensuring optimal drug exposure. Between 30–50% of CNS trials fail because patients are not following the assigned protocol. It is estimated that non-adherence based on pharmacokinetic (PK) data is as high as 39% in schizophrenia trials. An AI plat...
Autores principales: | Shafner, Laura, Chah, Chloe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5887427/ http://dx.doi.org/10.1093/schbul/sby016.329 |
Ejemplares similares
-
Use of a Novel Artificial Intelligence Platform on Mobile Devices to Assess Dosing Compliance in a Phase 2 Clinical Trial in Subjects With Schizophrenia
por: Bain, Earle E, et al.
Publicado: (2017) -
Artificial Intelligence Platform Demonstrates High Adherence in Patients Receiving Fixed-Dose Ledipasvir and Sofosbuvir: A Pilot Study
por: Litwin, Alain H, et al.
Publicado: (2020) -
Clinical validation of an artificial intelligence algorithm offering cross-platform detection of atrial fibrillation using smart device electrocardiograms
por: Mannhart, D, et al.
Publicado: (2022) -
Prospects for the use of artificial intelligence methods in autism spectrum disorders
por: Sidenkova, A., et al.
Publicado: (2023) -
Artificial intelligence in design
por: Pham Duc Truong
Publicado: (1991)